Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: cisplatin
Radiation: radiation therapy
Drug: etoposide
Drug: paclitaxel
Drug: carboplatin
Drug: docetaxel
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00042835

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Metastatic Cancer
Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020007

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Phase 1

Completed

Conditions: Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: cisplatin
Drug: topotecan hydrochloride
Biological: filgrastim

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00002913

Locations: 🇺🇸
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: paclitaxel
Biological: trastuzumab
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00042809

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: shark cartilage extract AE-941
Other: placebo
Drug: cisplatin
Drug: vinorelbine tartrate
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 756

Registration Number: NCT00005838

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: paclitaxel
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00028587

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Phase 2

Completed

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Squamous Cell Carcinoma of the Bladder
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions: Biological: trastuzumab
Drug: paclitaxel
Drug: carboplatin
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00005831

Locations: 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3

Completed

Conditions: Breast Adenocarcinoma
Stage IA Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
HER2 Positive Breast Carcinoma
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7

Interventions: Drug: Aromatase Inhibition Therapy
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Tamoxifen Citrate
Biological: Trastuzumab

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3436

Registration Number: NCT00005970

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Vermont and State Agricultural College, Burlington, Vermont, United States

and more 154 locations

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 589

Registration Number: NCT00004859

Locations: 🇺🇸
Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸
Swedish Covenant Hospital, Chicago, Illinois, United States

and more 230 locations

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Drug: paclitaxel
Drug: bryostatin 1

First Posted Date: 2003-01-27

Last Posted Date: 2021-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00031694

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy